Biogen (BSP:BIIB34) Current Accrued Expense : R$7,349 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Biogen Current Accrued Expense?

Biogen's Current Accrued Expense for the quarter that ended in Mar. 2024 was R$7,349 Mil.

Biogen's quarterly Current Accrued Expense declined from Sep. 2023 (R$17,590 Mil) to Dec. 2023 (R$7,105 Mil) but then increased from Dec. 2023 (R$7,105 Mil) to Mar. 2024 (R$7,349 Mil).

Biogen's annual Current Accrued Expense declined from Dec. 2021 (R$12,385 Mil) to Dec. 2022 (R$7,233 Mil) and declined from Dec. 2022 (R$7,233 Mil) to Dec. 2023 (R$7,105 Mil).

Biogen Current Accrued Expense Historical Data

The historical data trend for Biogen's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Current Accrued Expense Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

10,056.03

13,530.56

12,384.80

7,232.88

7,105.20

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															10,943.27	10,813.07	17,590.17	7,105.20	7,348.69

Biogen Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Biogen Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biogen's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines